Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Tirzepatide targets GIP and GLP-1 receptors and has approved uses in some jurisdictions
Verify the current MAC LCD for the most recent coverage determination before billing semaglutide or tirzepatide for non-diabetes indications Source: CMS LCD Database RCM teams managing injection billing must verify that their billing software reflects the April 2026 quarterly MPFSDB update
In any proper GLP-1 comparison , this shared mechanism is the starting point
Seven doses a week
P., & Guilford, F
Banerji, U
US$ 20.63
US$ 22.28
US$ 23.47
US$ 25.69
US$ 25.79
